Autoimmune retinopathy associated with monoclonal gammopathy of undetermined significance: a case report.


Journal

BMC ophthalmology
ISSN: 1471-2415
Titre abrégé: BMC Ophthalmol
Pays: England
ID NLM: 100967802

Informations de publication

Date de publication:
16 Apr 2020
Historique:
received: 21 05 2019
accepted: 06 04 2020
entrez: 18 4 2020
pubmed: 18 4 2020
medline: 18 3 2021
Statut: epublish

Résumé

Monoclonal gammopathy of undetermined significance (MGUS) is a plasma cell dyscrasia and precursor to multiple myeloma. It has known ocular manifestations, but has not previously been shown to have an association with autoimmune retinopathy. A 57 year-old female presented with 1 year of progressive, bilateral, peripheral vision loss, photopsias, and nyctalopia. Her fundus examination and extensive ancillary testing were concerning for hereditary versus autoimmune retinopathy. The patient was found to have anti-retinal antibodies against carbonic anhydrase II and enolase proteins with a negative genetic retinal dystrophy panel. Malignancy work-up was negative, but the patient was diagnosed with MGUS, a premalignant condition. The patient was treated with immunosuppressive therapies, with rituximab demonstrating the most robust therapeutic response with respect to patient symptoms and ophthalmic testing. MGUS should be considered as a potential etiology of autoimmune retinopathy in patients without other autoimmune or malignant disease processes. Immunosuppressive therapy may be helpful in limiting disease progression, with rituximab showing efficacy in retinopathy refractory to other agents.

Sections du résumé

BACKGROUND BACKGROUND
Monoclonal gammopathy of undetermined significance (MGUS) is a plasma cell dyscrasia and precursor to multiple myeloma. It has known ocular manifestations, but has not previously been shown to have an association with autoimmune retinopathy.
CASE PRESENTATION METHODS
A 57 year-old female presented with 1 year of progressive, bilateral, peripheral vision loss, photopsias, and nyctalopia. Her fundus examination and extensive ancillary testing were concerning for hereditary versus autoimmune retinopathy. The patient was found to have anti-retinal antibodies against carbonic anhydrase II and enolase proteins with a negative genetic retinal dystrophy panel. Malignancy work-up was negative, but the patient was diagnosed with MGUS, a premalignant condition. The patient was treated with immunosuppressive therapies, with rituximab demonstrating the most robust therapeutic response with respect to patient symptoms and ophthalmic testing.
CONCLUSIONS CONCLUSIONS
MGUS should be considered as a potential etiology of autoimmune retinopathy in patients without other autoimmune or malignant disease processes. Immunosuppressive therapy may be helpful in limiting disease progression, with rituximab showing efficacy in retinopathy refractory to other agents.

Identifiants

pubmed: 32299429
doi: 10.1186/s12886-020-01423-y
pii: 10.1186/s12886-020-01423-y
pmc: PMC7160953
doi:

Types de publication

Case Reports Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

153

Références

Arq Bras Oftalmol. 2005 Jul-Aug;68(4):539-41
pubmed: 16322842
Semin Immunopathol. 2008 Apr;30(2):127-34
pubmed: 18408929
Ocul Immunol Inflamm. 2015;23(5):405-9
pubmed: 24654565
N Engl J Med. 2018 Jan 18;378(3):241-249
pubmed: 29342381
Can J Ophthalmol. 2013 Dec;48(6):e168-70
pubmed: 24314436
Am J Ophthalmol. 2014 Feb;157(2):266-272.e1
pubmed: 24315290
BBA Clin. 2016 May 25;6:12-8
pubmed: 27331023
Clin Cancer Res. 2013 Mar 1;19(5):985-94
pubmed: 23224402
Haematologica. 2014 Jun;99(6):984-96
pubmed: 24658815
Korean J Ophthalmol. 2011 Jun;25(3):202-5
pubmed: 21655047
Orphanet J Rare Dis. 2017 Jul 15;12(1):129
pubmed: 28709429
Surv Ophthalmol. 2013 Sep-Oct;58(5):430-58
pubmed: 23969019
N Engl J Med. 2006 Mar 30;354(13):1362-9
pubmed: 16571879
Am J Ophthalmol. 2017 Aug;180:124-132
pubmed: 28483493
Ophthalmology. 2004 Mar;111(3):535-9
pubmed: 15019332
Retina. 2014 May;34(5):827-45
pubmed: 24646664
Arch Ophthalmol. 2009 Apr;127(4):390-7
pubmed: 19365013
Surv Ophthalmol. 2003 Jan-Feb;48(1):12-38
pubmed: 12559325

Auteurs

Emily A Eton (EA)

Kellogg Eye Center, University of Michigan, 1000 Wall Street, Ann Arbor, MI, 48105, USA. etone@med.umich.edu.

Gary Abrams (G)

Kresge Eye Institute, Wayne State University, 4717 St. Antoine, Detroit, MI, 48201, USA.

Naheed W Khan (NW)

Kellogg Eye Center, University of Michigan, 1000 Wall Street, Ann Arbor, MI, 48105, USA.

Abigail T Fahim (AT)

Kellogg Eye Center, University of Michigan, 1000 Wall Street, Ann Arbor, MI, 48105, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH